Related Experiment Video
Updated: Dec 28, 2025

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
RNA Splicing Defects in Hypertrophic Cardiomyopathy: Implications for Diagnosis and Therapy
Marta Ribeiro1,2, Marta Furtado1, Sandra Martins1
1Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Av Prof Egas Moniz, Edificio Egas Moniz, 1649-028 Lisboa, Portugal.
Insights
RNA analysis is improving genetic testing for hypertrophic cardiomyopathy (HCM). New variants affecting RNA splicing offer better diagnostic outcomes for this inherited heart condition.
Area of Science:
- Cardiovascular Genetics
- Molecular Biology
- Genomic Medicine
Background:
- Hypertrophic cardiomyopathy (HCM) is the most common inherited heart disease, often caused by sarcomere protein gene mutations.
- Genetic testing is crucial for HCM diagnosis and family management.
- High-throughput DNA sequencing has increased variants of uncertain significance, limiting genetic testing utility.
Purpose of the Study:
- To review recent discoveries in RNA mis-splicing in HCM.
- To explore the application of RNA therapeutics for HCM.
- To highlight advancements in genetic diagnostics for inherited heart conditions.
Main Methods:
- Review of recent scientific literature on RNA analysis in HCM.
- Analysis of studies identifying novel variants affecting RNA splicing.
- Overview of emerging RNA therapeutic strategies for HCM.
Main Results:
- RNA analysis is identifying new variants that interfere with splicing, improving diagnostic accuracy for HCM.
- These advancements address limitations posed by variants of uncertain significance in DNA sequencing.
- Research is exploring RNA-based therapeutic approaches for HCM.
Conclusions:
- RNA analysis represents a significant advancement in diagnosing hypertrophic cardiomyopathy.
- Identifying RNA splicing defects enhances the clinical utility of genetic testing for HCM.
- RNA therapeutics hold promise for future treatment strategies in HCM.
Abstract:
Hypertrophic cardiomyopathy (HCM), the most common inherited heart disease, is predominantly caused by mutations in genes that encode sarcomere-associated proteins. Effective gene-based diagnosis is critical for the accurate clinical management of patients and their family members. However, the introduction of high-throughput DNA sequencing approaches for clinical diagnostics has vastly expanded the number of variants of uncertain significance, leading to many inconclusive results that limit the clinical utility of genetic testing. More recently, developments in RNA analysis have been improving diagnostic outcomes by identifying new variants that interfere with splicing. This review summarizes recent discoveries of RNA mis-splicing in HCM and provides an overview of research that aims to apply the concept of RNA therapeutics to HCM.
Related Concept Videos
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
RNA Splicing
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Nonsense-mediated mRNA Decay
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
Chromatin Structure Regulates pre-mRNA Processing
The chromatin structure, especially...

